| __timestamp | BioMarin Pharmaceutical Inc. | Sanofi |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 8565000000 |
| Thursday, January 1, 2015 | 402271000 | 9496000000 |
| Friday, January 1, 2016 | 476593000 | 9592000000 |
| Sunday, January 1, 2017 | 554336000 | 10164000000 |
| Monday, January 1, 2018 | 604353000 | 9934000000 |
| Tuesday, January 1, 2019 | 680924000 | 9883000000 |
| Wednesday, January 1, 2020 | 737669000 | 9390000000 |
| Friday, January 1, 2021 | 759375000 | 9555000000 |
| Saturday, January 1, 2022 | 854009000 | 10539000000 |
| Sunday, January 1, 2023 | 937300000 | 10765000000 |
Unleashing the power of data
In the competitive landscape of the pharmaceutical industry, managing operational costs is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry giants, Sanofi and BioMarin Pharmaceutical Inc., from 2014 to 2023.
Sanofi, a global leader, consistently reported SG&A expenses that were approximately 10 times higher than those of BioMarin, reflecting its expansive market reach and operational scale. Over the decade, Sanofi's expenses showed a steady increase, peaking at over $10 billion in 2023, a 26% rise from 2014. In contrast, BioMarin's expenses grew by over 200%, indicating aggressive expansion and investment in its niche markets.
This financial trajectory highlights the strategic differences between a global pharmaceutical leader and a specialized biotech firm, offering insights into their operational priorities and market strategies.
Johnson & Johnson and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
AbbVie Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Sanofi or Teva Pharmaceutical Industries Limited
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc.
Breaking Down SG&A Expenses: United Therapeutics Corporation vs BioMarin Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioMarin Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Catalent, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs Grifols, S.A.: SG&A Expense Trends
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Evotec SE